Ahmed Alanazi/X
Jun 3, 2025, 11:55
Ahmed Alanazi: ASCO25 Plenary Session on ATOMIC Trial Results in Stage III Colon Cancer
Ahmed Alanazi, Department Program Director at King Fahad Medical City, shared a post on X:
“ASCO25 Plenary Session ATOMIC phase3 multi-center randomized open label clinical trial of adjuvant ATEZO+mFOLFOX vs mFOLFOX in resected stage III dMMR/MSI-H R0 colon cancer patients
– 3-years DFS 86.4% vs 76.6% HR 0.50
– OS data still immature
– Grade 3/4 weren’t siginficant betwen the two group
– most common irAE no new concerns
– Neutropenia was increased among atezo group.”
Read OncoDaily’s Special Articles about ASCO 2025:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
Highlights from ASCO 2025 Day 3
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 4, 2025, 08:13
Sep 4, 2025, 07:58
Sep 4, 2025, 07:52
Sep 4, 2025, 07:41
Sep 4, 2025, 07:15